Trial: 202109079

A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Phase

III

Principal Investigator

Hayashi, Robert

Disease Site

Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov